AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Chargeurs

CR
Bloomberg   CRI FP
Support Services  /  France  Web Site   |   Investors Relation
Strong 2025 ambitions, luxury flavour
Pros
  • Chargeurs is focusing on no-nonsense profitable growth, with a keen eye for developing businesses in niche markets with a low capital intensity
  • The creation of Healthcare Solutions is proof of astute and effective management, becoming a fantastic asset that has helped the group leapfrog its diversification ambitions
  • The main business, Protective Films, has a remarkable FCF potential as the need for quality in industrial processes is so ubiquitous
Cons
  • The firm is small in absolute terms and may fall below most investors' radars
  • Challenging market conditions in the fashion industry will continue weighing on the activities of CFT-PCC in FY21, with a material recovery expected not until FY22
  • While Chargeurs' CEO has gained a large majority control of Columbus (30% controlling shareholder) in early 2019, which is good news for minorities, the detailed ownership of Columbus remains unknown
Updates
19/12/22 StrategyFrom an industrialist to a luxury player?
15/11/22 EPSWe have incorporated the 9m 22 number...
15/11/22 DCFIn line with the downward revision of our ...
10/11/22 EarningsQ3 22: a subdued quarter
22/09/22 EPSFollowing the publication of the H1 22 res...
22/09/22 DCFOur DCF-based valuation sees a margina...
15/09/22 Other newsThe up-and-coming luxury player
12/09/22 EarningsH1 22: an encouraging start to FY 2022 d...
13/05/22 EarningsUpbeat start to 2022 propelled by strong ...
24/03/22 EPSWe have incorporated the FY21 figures, ...
24/03/22 NAVWe have adjusted the value of the differe...
24/03/22 DCFOur DCF-based valuation sees a margina...
18/02/22 EarningsFY21: CPF achieves record year, group’s...
11/11/21 EarningsQ3 performance confirms our FY view
23/09/21 LatestChange of valuation profile
13/09/21 EarningsH1 21: strong execution and record order...
05/05/21 TargetThe adjustments made to our FY21-22 E...
05/05/21 EPSFollowing the publication of the record Q...
05/05/21 EarningsProtective Films and Healthcare Solution...
29/04/21 TargetThe valuation increases across the differ...
29/04/21 EPSThe significant upgrade in our FY21-22 E...
29/04/21 NAVWe have updated our estimated NAV by i...
29/04/21 DCFThe rise in our DCF-based valuation is dri...
20/04/21 EPSWe have revised our earnings expectatio...
20/04/21 NAVThe valuation of Chargeurs' business line...
24/02/21 EarningsCHS leads FY20 record result as Charge...
28/01/21 EPSWe have raised our EPS estimates for F...
28/01/21 EarningsFY20 ends on a high note as Protective F...
11/11/20 EarningsHealthcare-led Q3 lifts full-year outlook
11/11/20 EPSOur FY20 EPS estimate increases on the...
14/09/20 TargetOur target price is virtually unchanged foll...
14/09/20 EPSOur FY20 EPS estimate sees a major up...
14/09/20 NAVOur NAV/SOTP valuation is mainly impac...
14/09/20 EarningsH1: an absolute home run
29/04/20 EarningsNew healthcare products activity unlocks ...
17/04/20 TargetThe cut to our target price reflects the mo...
17/04/20 EPSThe lower FY19 EPS reflect the costs rel...
17/04/20 NAVOur estimated NAV remains quite conser...
17/04/20 DCFWe maintain our base assumption which ...
14/04/20 LatestNew protective equipment activity to help ...
09/03/20 EarningsStaying on course with strategic roadmap...
03/02/20 EarningsFY19 sets a sound foundation for growth ...
28/01/20 M&A /Corp.Strategic move towards museum servicin...
28/01/20 TargetOur increased TP sees its biggest impact...
28/01/20 NAVWe have included the acquisition of D&P ...
18/11/19 EarningsQ3: another robust quarterly showing
18/11/19 EPSWe have slightly trimmed our 2019 EPS ...
23/09/19 EPSOur EPS estimates decreased on the bac...
23/09/19 DCFOur DCF valuation is impacted by our low...
Target
Upside 76.3%
Price (€) 15.7
Market Cap (€M) 391
Perf. 1W: 1.29%
Perf. 1M: 6.44%
Perf. 3M: 20.4%
Perf Ytd: 11.5%
10 day relative perf. to stoxx600: 1.17%
20 day relative perf. to stoxx600: 0.78%